Exelixis (EXEL) Cash & Current Investments (2010 - 2026)
Exelixis (EXEL) recorded quarterly Cash & Current Investments of $777.2 million in Q2 2026, down 26.62% quarter-over-quarter from $1.1 billion in Q1 2026, and down 24.64% on a YoY basis from $1.0 billion in Q2 2025.
Exelixis (EXEL) Cash & Current Investments (2010 - 2026) Analysis & Trends
Exelixis' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $777.2 million for Q2 2026.
- In Q2 2026, Cash & Current Investments fell 24.64% year-over-year to $777.2 million; the TTM figure through Apr 2026 stood at $777.2 million (down 24.64% YoY), while the FY2026 annual figure was $1.1 billion, down 4.7% from the prior year.
- Cash & Current Investments was $777.2 million for Q2 2026 at Exelixis, down from $1.1 billion in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $1.6 billion in Q2 2022 to a low of $777.2 million in Q2 2026.
- Historically, Cash & Current Investments has averaged $1.2 billion across 5 years, with a median of $1.1 billion in 2023.
- The sharpest annual moves came in 2022 and 2023: Cash & Current Investments jumped 32.46% in 2022, then retreated 28.68% in 2023.
- A 5-year view of Cash & Current Investments shows it stood at $1.3 billion in 2022, then decreased by 23.93% to $995.3 million in 2023, then climbed by 19.48% to $1.2 billion in 2024, then slipped by 16.87% to $988.5 million in 2025, then dropped by 21.38% to $777.2 million in 2026.
- The last three Cash & Current Investments figures came in at $777.2 million (Q2 2026), $1.1 billion (Q1 2026), and $988.5 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 2.77 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 18.44 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Exelixis | 13.61 Bn | 12.83 Bn | 590.86 Mn | 777.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 777.21 Mn |
| Jan 2, 2026 | 1.06 Bn |
| Oct 3, 2025 | 988.54 Mn |
| Jul 4, 2025 | 791.10 Mn |
| Apr 4, 2025 | 1.03 Bn |
| Jan 3, 2025 | 1.11 Bn |
| Sep 27, 2024 | 1.19 Bn |
| Jun 28, 2024 | 1.00 Bn |
| Mar 29, 2024 | 963.26 Mn |
| Dec 29, 2023 | 995.30 Mn |
| Sep 29, 2023 | 1.10 Bn |
| Jun 30, 2023 | 1.27 Bn |
| Mar 31, 2023 | 1.31 Bn |
| Dec 30, 2022 | 1.31 Bn |
| Sep 30, 2022 | 1.55 Bn |
| Jul 1, 2022 | 1.53 Bn |
| Apr 1, 2022 | 1.57 Bn |
| Dec 31, 2021 | 1.47 Bn |
| Oct 1, 2021 | 1.40 Bn |
| Jul 2, 2021 | 1.35 Bn |